Levodopa News and Research

RSS

Merck Serono's Kuvan receives European marketing authorization

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that the European Commission has granted marketing authorization for Kuvan(R) for the treatment of hyperphenylalaninemia (HPA) in phenylketonuria (PKU) or BH4 deficient patients.

10 Dec 2008

Addex Parkinson's product progressing in early clinical trials

Addex Pharmaceuticals has announced that it has completed the first part of a two-part Phase I clinical trial to evaluate the newly developed modified release formulation of ADX48621. ADX48621 is scheduled to start a Phase IIa proof of concept study for the treatment of levodopa associated dyskinesia in Parkinson's disease during the first half of 2009.

15 Oct 2008

Cell-based therapy shows promise in patients with Parkinson's disease

Rush University Medical Center neurosurgeon Dr. Roy A. E. Bakay and colleagues from Emory University, Atlanta found the therapy Spheramine was well-tolerated and patients experienced improvement in Parkinsonian symptoms (tremor, rigidity, slowness of movements, and impaired balance and coordination.)

28 Apr 2008

Dopamine agonists reduce motor complications in Parkinson's disease, but increase other side-effects

Dopamine agonists are increasingly used to treat people with Parkinson's disease, but there is a debate about how well they work.

17 Apr 2008

Nicotine reduces levodopa-induced dyskinesias

The Parkinson's Institute and Clinical Center today announced research showing that intermittent nicotine treatment reduces medication-induced dyskinesias by as much as 50 percent in models of Parkinson's disease.

24 Oct 2007

People with early Parkinson's more likely to develop hallucinations, sleepiness and swelling

People with early Parkinson's disease report a higher than anticipated development or worsening of hallucinations, sleepiness, and swelling.

10 Jul 2007

Phase III data on Safinamide in Parkinson's disease

Merck Serono S.A. has announced that Phase III data on safinamide, a new agent in Phase III development for the treatment of Parkinson's disease symptoms, were presented by Professor Fabrizio Stocchi at the American Academy of Neurology 59th Annual Meeting in Boston, Massachusetts, USA.

4 May 2007

Submission of NDA for Istradefylline(KW-6002), an investigational anti-Parkinson's disease drug

Kyowa Hakko Kogyo Co. has announced that Kyowa Pharmaceutical, Inc., its wholly owned U.S subsidiary, submitted on April 25, 2007 a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Istradefylline(KW-6002), its investigational drug for Parkinson's disease.

30 Apr 2007

Drugs that adjust dopamine levels in the brain greatly affect how people react to success and failure

In a first-of-its-kind study on humans, researchers measured how dopamine-related drugs affect the striatum, a part of the brain that is stimulated by rewards.

27 Apr 2007

Jefferson participates in global study to extend effectiveness of drug for Parkinson's

After Parkinson's disease patients use the drug levodopa or L-dopa for several years as a treatment for restoring the cellular communication that controls muscle movement by replacing lost dopamine, they begin to experience motor complications that include a shortened response to each dose of L-dopa.

19 Apr 2007

Ropinirole reduces "off" time in Parkinson's

Parkinson disease patients taking the drug, ropinirole 24-hour prolonged release significantly reduced their daily "off" time in which Parkinson's symptoms like tremor, slowness, stiffness, and walking difficulty return as drugs wear off, according to a study published in the April 3, 2007, issue of Neurology, the scientific journal of the American Academy of Neurology.

4 Apr 2007

Withdrawal of Pergolide products

The U.S. Food and Drug Administration (FDA) today announced that manufacturers of pergolide drug products, which are used to treat Parkinson's disease, will voluntarily remove these drugs from the market because of the risk of serious damage to patients' heart valves.

29 Mar 2007

Researchers look at whether creatine slows progression of Parkinson's disease

Researchers at the University of Rochester Medical Center are leading one of the largest clinical trials ever for Parkinson's disease.

25 Mar 2007

Creatine may help Parkinson's patients by giving an energy boost to dying cells

Whether a supplement used by athletes to boost energy levels and build muscle can slow progression of Parkinson's disease is the focus of a North American study.

22 Mar 2007

Levodopa improves tremors, involuntary movements in Parkinson patients

A drug used to treat epilepsy has been found to significantly improve tremors, motor fluctuations, and other involuntary movements, or dyskinesias, in patients with Parkinson disease, according to a study published in Neurology, the scientific journal of the American Academy of Neurology.

2 Jan 2007